Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi PharmaTech Surprises with a 5% Q1 Revenue Increase

publication date: May 15, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

WuXi PharmaTech (药明康德) announced a 5% increase in Q1 revenues, but net income fell 15% and earnings per share dropped an even-greater 22% during the period. Stressing the positive, WuXi said its core business, China CRO laboratory services, rose a healthy 33%. The problem was in contract manufacturing, whose revenues sank by 81%. Evidently, WuXi has done a good job of preparing Wall Street for even worse results, because shares of WuXi moved sharply higher following the earnings announcement. More details...

Stock Symbol: (NYSE: WX)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors